Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.
Explore NowDelveInsight’s ‘Diabetic Retinopathy (DR) – Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Diabetic Retinopathy (DR), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Diabetic Retinopathy (DR) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted Diabetic Retinopathy (DR) symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current Diabetic Retinopathy (DR) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2018–2030
Diabetic Retinopathy (DR) Overview
Aging of the world population, along with the diabetic epidemic, has created an ongoing, sharp increase in the incidence of many eye diseases. Diabetic retinopathy, in particular, is among the most frequent complication of diabetes. It is caused by damage to the blood vessels of light-sensitive tissue at the back of the eyes. The condition can develop in anyone who has type 1 or type 2 diabetes. The risk of developing diabetic retinopathy is higher, the longer a person has diabetes, especially if it is poorly controlled. Diabetic macular edema is a type of diabetic retinopathy and is defined by significant swelling of the retinal tissue caused by retinal vessels leaking blood and fluid into the macula. Diabetic macular edema is a leading cause of vision loss for people with diabetes.
Though anti-VEGF therapy has proven a breakthrough for Diabetic Retinopathy, there is still a third of sufferers with low or no response. Anti-VEGFs are increasingly available on a global scale but come at high financial cost and treatment burden. There are major opportunities for biosimilars, novel biochemical pathways, and improved treatment regimens, along with delivery techniques, which is aimed at providing more options and easing the patient burden
Diabetic Retinopathy (DR) Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Diabetic Retinopathy (DR) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Diabetic Retinopathy (DR) market report gives a thorough understanding of Diabetic Retinopathy (DR) symptoms by including details such as disease definition, symptoms, causes, physiology, and diagnosis. It also provides Diabetic Retinopathy (DR) symptoms of treatment algorithms and treatment guidelines for Diabetic Retinopathy (DR) symptoms in the US, Europe, and Japan.
Diabetic retinopathy is detected during an eye examination that includes visual acuity test, pupil dilation, ophthalmoscopy or fundus photography, and others.
For diabetic retinopathy that is threatening or affecting the patient’s sight, the main treatments are:
a) laser treatment – to treat the growth of new blood vessels at the back of the eye (retina) in cases of proliferative diabetic retinopathy, and to stabilize some cases of maculopathy
b) eye injections – to treat severe maculopathy ‘’that is threatening your sight
c) eye surgery – to remove blood or scar tissue from the eye if laser treatment is not possible because retinopathy is too advanced.
The Diabetic Retinopathy (DR) symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The diagnosed cases of Diabetic Retinopathy (DR) is increasing in 7MM during the study period, i.e., 2018–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Diabetic Retinopathy (DR) symptoms epidemiology segmented as the Total Diagnosed Prevalent cases of Diabetic Retinopathy (DR), Gender-Specific cases of Diabetic Retinopathy (DR), Age-Specific cases of Diabetic Retinopathy (DR), and Severity-Specific cases of Diabetic Retinopathy (DR). The report includes the prevalent scenario of Diabetic Retinopathy (DR) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
The epidemiology segment also provides the Diabetic Retinopathy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The drug chapter segment of the Diabetic Retinopathy (DR) report encloses the detailed analysis of Diabetic Retinopathy (DR) early stage (Phase-I/II, II, and III) pipeline drugs, and marketed drugs. It also helps to understand the Diabetic Retinopathy (DR) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Diabetic Retinopathy (DR) Marketed Drug
LUCENTIS: Genentech
LUCENTIS (Ranibizumab), a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy in patients with DME, and Myopic Choroidal Neovascularization (mCNV).
EYLEA: Regeneron Pharmaceuticals
EYLEA (Aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).Diabetic Retinopathy (DR) Emerging Drug
Brolucizumab: Novartis Pharmaceuticals
Brolucizumab (RTH258) is a humanized single-chain antibody fragment (scFv) and the most clinically advanced, humanized single-chain antibody fragment to reach this stage of development. Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation, and drug delivery characteristics.
Faricimab: Roche
Faricimab is a novel, bispecific antibody that simultaneously binds to and inhibits both vascular endothelial growth factor A (VEGF-A) and Angiopoietin-2 (Ang-2), and is the first bispecific antibody designed specifically for the treatment of retinal eye diseases.
and other therapies in the report…
Products detail in the report…
The Diabetic Retinopathy (DR) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Diabetic Retinopathy (DR) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Diabetic Retinopathy (DR) market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Diabetic Retinopathy (DR) market in 7MM is expected to grow in the study period 2018–2030.
Current treatments for diabetic retinopathies are limited, and the focus relies heavily on the presence of macular edema. Historically, traditional therapies such as vitrectomy, photocoagulation, and corticosteroids were used. These offer no opportunity for vision improvement and come with high rates of complications. Anti-vascular endothelial growth factor (anti-VEGF) drugs have made a meaningful improvement to DME sufferers over the past decade, but even these have limited to no success in third or more sufferers. Thus, there remains a high-unmet patient need and keen interest on the part of investigators for the continued development of all treatment modalities and biochemical pathways. Fortunately, there is a robust pipeline of potential new treatments currently in Phases II and III.
Lucentis was the first anti-VEGF approved that demonstrated sustained maintenance of vision improvement. Currently, Eylea is the accepted standard of care and the market-leading drug in virtually all retinal disorders. It has seen particularly rapid growth in the DME market as studies have shown that it may be superior to the alternatives in DME patients with more severe disease. Interestingly, Avastin is used off label in ocular indications but is widely reimbursed. The reasons for choosing one anti-VEGF over another are multifactorial and include retinal thickness, disease progression, best-corrected visual acuity (BCVA), reimbursement, and patient and family influences.
Key Findings
This section includes a glimpse of the Diabetic Retinopathy (DR) market in 7MM. The market size of Diabetic Retinopathy (DR) in the seven major markets was USD 3,127.6 Million in 2020.
The United States Market Outlook
This section provides the total Diabetic Retinopathy (DR) market size and market size by therapies in the United States.
The United States accounts for the largest market size of Diabetic Retinopathy (DR) in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
EU-5 Countries: Market Outlook
The total Diabetic Retinopathy (DR) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Diabetic Retinopathy (DR) market Size and market Size by therapies in Japan are also mentioned.
This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Diabetic Retinopathy (DR) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
The report provides insights into the therapeutic candidate in Phase I, II and III stage. It also analyses Diabetic Retinopathy (DR) key players involved in developing targeted therapeutics.
Major players include Novartis Pharmaceuticals, Roche, Adverum Biotechnologies, Kubota Vision, KalVista Pharmaceuticals, and Allegro Ophthalmics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Diabetic Retinopathy (DR) emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the early stages of product development and well after product launch. In the report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Despite the long-standing availability of professional guidelines for diabetic retinopathy screening, only 55.7% of adults with diabetes preferred commercial HMO plans and 46.9% of those in commercial preferred provider organization (PPO) plans, received screening in 2013, according to the Healthcare Effectiveness Data and Information Set (HEDIS). HEDIS is a tool used by US health plans to measure performance on important dimensions of care and service. Yet, data are suggesting that patients with diabetes who receive guideline-recommended screening and care for diabetic retinopathy have better outcomes than those who do not. For example, a study assessing the effect of receiving guideline-recommended care with the onset of diabetic retinopathy and its progression in Medicare beneficiaries with diabetes found that those who received such care were diagnosed with background diabetic retinopathy earlier than those who did not, and they experienced lower rates of the onset of diminished vision or blindness. Furthermore, the data from a novel study that incorporated a simulation of a population of veterans with diabetes who had not yet developed diabetic retinopathy showed that vision loss associated with diabetic retinopathy increased as the screening interval was extended from 1 year to 5 years.
To keep up with current market trends, we take KOLs and SME’s opinion working in Diabetic Retinopathy (DR) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Diabetic Retinopathy (DR) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Diabetic Retinopathy (DR) Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
1. Key Insights
2. Executive summary
3. Organizations
4. Diabetic Retinopathy: Market Overview at a Glance
4.1. Total Market Share (%) Distribution of Diabetic Retinopathy in 2020
4.2. Total Market Share (%) Distribution of Diabetic Retinopathy in 2030
5. Diabetic Retinopathy: Market Overview at a Glance
5.1. Introduction
5.2. Diabetes Mellitus
5.2.1. Type 1 Diabetes Mellitus
5.2.2. Type 2 Diabetes Mellitus
5.3. Pathophysiology
5.4. Clinical Presentation
5.5. Diabetic Retinopathy Symptoms
5.6. Diabetic Retinopathy Risk Factors
5.7. Diabetic Retinopathy Classification
5.8. Diagnosis of Diabetic Retinopathy
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Assumptions and Rationale
6.3. Total cases of Diabetic Retinopathy in the 7MM
6.4. United States
6.4.1. Total Diagnosed cases of Diabetic Retinopathy in the United States
6.4.2. Gender-specific cases of Diabetic Retinopathy in the United States
6.4.3. Age-specific cases of Diabetic Retinopathy in the United States
6.4.4. Severity-specific cases of Diabetic Retinopathy in the United States
6.5. EU5 Countries
6.5.1. Germany
6.5.1.1. Total Diagnosed cases of Diabetic Retinopathy in Germany
6.5.1.2. Gender-specific cases of Diabetic Retinopathy in Germany
6.5.1.3. Age-specific cases of Diabetic Retinopathy in Germany
6.5.1.4. Severity-specific cases of Diabetic Retinopathy in Germany
6.5.2. France
6.5.2.1. Total Diagnosed cases of Diabetic Retinopathy in France
6.5.2.2. Gender-specific cases of Diabetic Retinopathy in France
6.5.2.3. Age-specific cases of Diabetic Retinopathy in France
6.5.2.4. Severity-specific cases of Diabetic Retinopathy in France
6.5.3. Italy
6.5.3.1. Total Diagnosed cases of Diabetic Retinopathy in Italy
6.5.3.2. Gender-specific cases of Diabetic Retinopathy in Italy
6.5.3.3. Age-specific cases of Diabetic Retinopathy in Italy
6.5.3.4. Severity-specific cases of Diabetic Retinopathy in Italy
6.5.4. Spain
6.5.4.1. Total Diagnosed cases of Diabetic Retinopathy in Spain
6.5.4.2. Gender-specific cases of Diabetic Retinopathy in Spain
6.5.4.3. Age-specific cases of Diabetic Retinopathy in Spain
6.5.4.4. Severity-specific cases of Diabetic Retinopathy in Spain
6.5.5. United Kingdom
6.5.5.1. Total Diagnosed cases of Diabetic Retinopathy in the United Kingdom
6.5.5.2. Gender-specific cases of Diabetic Retinopathy in the United Kingdom
6.5.5.3. Age-specific cases of Diabetic Retinopathy in the United Kingdom
6.5.5.4. Severity-specific cases of Diabetic Retinopathy in the United Kingdom
6.6. Japan
6.6.1. Total Diagnosed cases of Diabetic Retinopathy in Japan
6.6.2. Gender-specific cases of Diabetic Retinopathy in Japan
6.6.3. Age-specific cases of Diabetic Retinopathy in Japan
6.6.4. Severity-specific cases of Diabetic Retinopathy in Japan
7. Treatment of Diabetic Retinopathy
8. Unmet Needs
9. Marketed Drugs
9.1. Lucentis: Genentech
9.1.1. Drug Description
9.1.2. Regulatory Milestones
9.1.3. Other Development Activities
9.1.4. Clinical Development
9.1.5. Safety and Efficacy
9.1.6. Product Profile
9.2. Eylea: Regeneron Pharmaceuticals
9.2.1. Drug Description
9.2.2. Regulatory Milestones
9.2.3. Other Development Activities
9.2.4. Clinical Development
9.2.5. Safety and Efficacy
9.2.6. Product Profile
10. Emerging Therapies
10.1. Key Cross Competition
10.2. KSI-301: Kodiak Sciences
10.2.1. Product Description
10.2.2. Other Developmental Activities
10.2.3. Clinical Development
10.2.4. Safety and Efficacy
10.2.5. Product Profile
10.3. Brolucizumab: Novartis Pharmaceuticals
10.3.1. Drug Description
10.3.2. Other Developmental Activities
10.3.3. Clinical Development
10.3.4. Safety and Efficacy
10.3.5. Product Profile
10.4. Faricimab: Roche
10.4.1. Drug Description
10.4.2. Clinical Development
10.4.3. Safety and Efficacy
10.4.4. Product Profile
10.5. ADVM-022: Adverum Biotechnologies
10.5.1. Drug Description
10.5.2. Other Developmental Activities
10.5.3. Clinical Development
10.5.4. Safety and Efficacy
10.5.5. Product Profile
10.6. GB-102: Graybug Vision
10.6.1. Drug Description
10.6.2. Clinical Development
10.6.3. Safety and Efficacy
10.6.4. Product Profile
10.7. Emixustat Hydrochloride: Kubota Vision Inc.
10.7.1. Drug Description
10.7.2. Other Developmental Activities
10.7.3. Clinical Development
10.7.4. Safety and Efficacy
10.7.5. Product Profile
10.8. KVD001: KalVista Pharmaceuticals Ltd.
10.8.1. Drug Description
10.8.2. Other Developmental Activities
10.8.3. Clinical Development
10.8.4. Safety and Efficacy
10.8.5. Product Profile
10.9. LKA651: Novartis Pharmaceuticals
10.9.1. Drug Description
10.9.2. Clinical Development
10.9.3. Product Profile
10.10. Risuteganib: Allegro Ophthalmics
10.10.1. Drug Description
10.10.2. Other Developmental Activities
10.10.3. Clinical Development
10.10.4. Safety and Efficacy
10.10.5. Product Profile
10.11. RG7774: Roche
10.11.1. Drug Description
10.11.2. Clinical Development
10.11.3. Product Profile
10.12. BI 764524: Boehringer Ingelheim
10.12.1. Drug Description
10.12.2. Other Developmental Activities
10.12.3. Clinical Development
10.12.4. Product Profile
11. Diabetic Retinopathy: Seven Major Market Analysis
11.1. Key Findings
11.2. Market Size of Diabetic Retinopathy in 7MM
12. 7MM Market Outlook
13. United States Market Size
13.1. Total Market Size of Diabetic Retinopathy in the United States
13.2. Total Market Size of Diabetic Retinopathy by Therapies in the United States
13.3. Germany
13.3.1. Total market size of Diabetic Retinopathy in Germany
13.3.2. Total market size of Diabetic Retinopathy by Therapies in Germany
13.4. France
13.4.1. Total market size of Diabetic Retinopathy in France
13.4.2. Total Market size of Diabetic Retinopathy by Therapies in France
13.5. Italy
13.5.1. Total market size of Diabetic Retinopathy in Italy
13.5.2. Total Market size of Diabetic Retinopathy by Therapies in Italy
13.6. Spain
13.6.1. Total Market Size of Diabetic Retinopathy in Spain
13.6.2. Total market size of Diabetic Retinopathy by Therapies in Spain
13.7. United Kingdom
13.7.1. Total market size of Diabetic Retinopathy in the United Kingdom
13.7.2. Total market size of Diabetic Retinopathy by Therapies in the UK
13.8. Japan
13.8.1. Total market size of Diabetic Retinopathy in Japan
13.8.2. Total market size of Diabetic Retinopathy by Therapies in Japan
14. Market Drivers
15. Market Barriers
16. SWOT Analysis
17. Market Access and Reimbursement
18. Case Study
18.1. A case study of a patient with diabetic retinopathy
18.2. A case report on proliferative diabetic retinopathy with a marked sheathing of the retinal arteries following vitrectomy
18.3. Proliferative diabetic retinopathy in a 16-year-old: A case report
18.4. A case of proliferative diabetic retinopathy with HIV infection in which HAART possibly influenced the prognosis of visual function
19. KOL Views
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22 Disclaimer
23 About DelveInsight
List of Table
Table 1: Summary of Diabetic Retinopathy (DR), Market, Epidemiology, and Key Events (2018–2030)
Table 2: Risk Factors
Table 3: Genetic polymorphisms and diabetic retinopathy
Table 4: Total cases of Diabetic Retinopathy in the 7MM (2018–2030)
Table 5: Total Diagnosed cases of Diabetic Retinopathy in the United States (2018–2030)
Table 6: Gender-specific cases of Diabetic Retinopathy in the US (2018–2030)
Table 7: Age-specific cases of Diabetic Retinopathy in the US (2018–2030)
Table 8: Severity-specific cases of Diabetic Retinopathy in the US (2018–2030)
Table 9: Total Diagnosed cases of Diabetic Retinopathy in Germany (2018–2030)
Table 10: Gender-specific cases of Diabetic Retinopathy in Germany (2018–2030)
Table 11: Age-specific cases of Diabetic Retinopathy in Germany (2018–2030)
Table 12: Severity-specific cases of Diabetic Retinopathy in Germany (2018–2030)
Table 13: Total Diagnosed cases of Diabetic Retinopathy in France (2018–2030)
Table 14: Gender-specific cases of Diabetic Retinopathy in France (2018–2030)
Table 15: Age-specific cases of Diabetic Retinopathy in France (2018–2030)
Table 16: Severity-specific cases of Diabetic Retinopathy in France (2018–2030)
Table 17: Total Diagnosed cases of Diabetic Retinopathy in Italy (2018–2030)
Table 18: Gender-specific cases of Diabetic Retinopathy in Italy (2018–2030)
Table 19: Age-specific cases of Diabetic Retinopathy in Italy (2018–2030)
Table 20: Severity-specific cases of Diabetic Retinopathy in Italy (2018–2030)
Table 21: Total Diagnosed cases of Diabetic Retinopathy in Spain (2018–2030)
Table 22: Gender-specific cases of Diabetic Retinopathy in Spain (2018–2030)
Table 23: Age-specific cases of Diabetic Retinopathy in Spain (2018–2030)
Table 24: Severity-specific cases of Diabetic Retinopathy in Spain (2018–2030)
Table 25: Total Diagnosed cases of Diabetic Retinopathy in the United Kingdom (2018–2030)
Table 26: Gender-specific cases of Diabetic Retinopathy in the UK (2018–2030)
Table 27: Age-specific cases of Diabetic Retinopathy in the UK (2018–2030)
Table 28: Severity-specific cases of Diabetic Retinopathy in the UK (2018–2030)
Table 29: Total Diagnosed cases of Diabetic Retinopathy in Japan (2018–2030)
Table 30: Gender-specific cases of Diabetic Retinopathy in Japan (2018–2030)
Table 31: Age-specific cases of Diabetic Retinopathy in Japan (2018–2030)
Table 32: Severity-specific cases of Diabetic Retinopathy in Japan (2018–2030)
Table 33: Lucentis, Clinical Trial Description, 2021
Table 34: Eylea, Clinical Trial Description, 2021
Table 35: KSI-301, Clinical Trial Description, 2021
Table 36: Brolucizumab, Clinical Trial Description, 2021
Table 37: Faricimab, Clinical Trial Description, 2021
Table 38: ADVM‑022, Clinical Trial Description, 2021
Table 39: GB-102, Clinical Trial Description, 2021
Table 40: Emixustat Hydrochloride, Clinical Trial Description, 2021
Table 41: KVD001, Clinical Trial Description, 2021
Table 42: LKA651, Clinical Trial Description, 2021
Table 43: Luminate, Clinical Trial Description, 2021
Table 44: RG7774, Clinical Trial Description, 2021
Table 45: BI 764524, Clinical Trial Description, 2021
Table 46: Market Size of Diabetic Retinopathy in the 7MM, in USD Million (2018–2030)
Table 47: US Market Size of Diabetic Retinopathy in USD Million (2018–2030)
Table 48: The US Market Size of Diabetic Retinopathy in USD Million (2018–2030)
Table 49: Market Size of Diabetic Retinopathy in Germany, in USD Million (2018–2030)
Table 50: Market Size of Diabetic Retinopathy in Germany, in USD Million (2018–2030)
Table 51: Market Size of Diabetic Retinopathy in France, in USD Million (2018–2030)
Table 52: Market Size of Diabetic Retinopathy in France, in USD Million (2018–2030)
Table 53: Market Size of Diabetic Retinopathy in Italy, in USD Million (2018–2030)
Table 54: Market Size of Diabetic Retinopathy in Italy, in USD Million (2018–2030)
Table 55: Market Size of Diabetic Retinopathy in Spain, in USD Million (2018–2030)
Table 56: Market Size of Diabetic Retinopathy in Spain, in USD Million (2018–2030)
Table 57: Market Size of Diabetic Retinopathy in the UK, in USD Million (2018–2030)
Table 58: Market Size of Diabetic Retinopathy in the UK, in USD Million (2018–2030)
Table 59: Market Size of Diabetic Retinopathy in Japan, in USD Million (2018–2030)
Table 60: Market Size of Diabetic Retinopathy in Japan, in USD Million (2018–2030)
List of Figures
Figure 1: Pathways involved in Diabetic Retinopathy
Figure 2: Risk factors for Diabetic retinopathy
Figure 3: Total cases of Diabetic Retinopathy in the 7MM (2018–2030)
Figure 4: Total Diagnosed cases of Diabetic Retinopathy in the United States (2018–2030)
Figure 5: Gender-specific cases of Diabetic Retinopathy in the US (2018–2030)
Figure 6: Age-specific cases of Diabetic Retinopathy in the US (2018–2030)
Figure 7: Severity-specific cases of Diabetic Retinopathy in the US (2018–2030)
Figure 8: Total Diagnosed cases of Diabetic Retinopathy in Germany (2018–2030)
Figure 9: Gender-specific cases of Diabetic Retinopathy in Germany (2018–2030)
Figure 10: Age-specific cases of Diabetic Retinopathy in Germany (2018–2030)
Figure 11: Severity-specific cases of Diabetic Retinopathy in Germany (2018–2030)
Figure 12: Total Diagnosed cases of Diabetic Retinopathy in France (2018–2030)
Figure 13: Gender-specific cases of Diabetic Retinopathy in France (2018–2030)
Figure 14: Age-specific cases of Diabetic Retinopathy in France (2018–2030)
Figure 15: Severity-specific cases of Diabetic Retinopathy in France (2018–2030)
Figure 16: Total Diagnosed cases of Diabetic Retinopathy in Italy (2018–2030)
Figure 17: Gender-specific cases of Diabetic Retinopathy in Italy (2018–2030)
Figure 18: Age-specific cases of Diabetic Retinopathy in Italy (2018–2030)
Figure 19: Severity-specific cases of Diabetic Retinopathy in Italy (2018–2030)
Figure 20: Total Diagnosed cases of Diabetic Retinopathy in Spain (2018–2030)
Figure 21: Gender-specific cases of Diabetic Retinopathy in Spain (2018–2030)
Figure 22: Age-specific cases of Diabetic Retinopathy in Spain (2018–2030)
Figure 23: Severity-specific cases of Diabetic Retinopathy in Spain (2018–2030)
Figure 24: Total Diagnosed cases of Diabetic Retinopathy in the United Kingdom (2018–2030)
Figure 25: Gender-specific cases of Diabetic Retinopathy in the UK (2018–2030)
Figure 26: Age-specific cases of Diabetic Retinopathy in the UK (2018–2030)
Figure 27: Severity-specific cases of Diabetic Retinopathy in the UK (2018–2030)
Figure 28: Total Diagnosed cases of Diabetic Retinopathy in Japan (2018–2030)
Figure 29: Gender-specific cases of Diabetic Retinopathy in Japan (2018–2030)
Figure 30: Age-specific cases of Diabetic Retinopathy in Japan (2018–2030)
Figure 31: Severity-specific cases of Diabetic Retinopathy in Japan (2018–2030)
Figure 32: Treatment guidelines by the American Academy of Ophthalmology
Figure 33: Unmet Needs
Figure 34: Market Size of Diabetic Retinopathy in USD Million (2018–2030)
Figure 35: Market Size of Diabetic Retinopathy in the US, USD Millions (2018–2030)
Figure 36: Market Size of Diabetic Retinopathy in the US by therapies, USD Millions (2018–2030)
Figure 37: Market Size of Diabetic Retinopathy in Germany, USD Millions (2018–2030)
Figure 38: Market Size of Diabetic Retinopathy in Germany by therapies, USD Millions (2018–2030)
Figure 39: Market Size of Diabetic Retinopathy in France, USD Millions (2018–2030)
Figure 40: Market Size of Diabetic Retinopathy in France by therapies, USD Millions (2018–2030)
Figure 41: Market Size of Diabetic Retinopathy in Italy, USD Millions (2018–2030)
Figure 42: Market Size of Diabetic Retinopathy in Italy by therapies, USD Millions (2018–2030)
Figure 43: Market Size of Diabetic Retinopathy in Spain, USD Millions (2018–2030)
Figure 44: Market Size of Diabetic Retinopathy in Spain by therapies, USD Millions (2018–2030)
Figure 45: Market Size of Diabetic Retinopathy in the UK, USD Millions (2018–2030)
Figure 46: Market Size of Diabetic Retinopathy in the UK by therapies, USD Millions (2018–2030)
Figure 47: Market Size of Diabetic Retinopathy in Japan, USD Millions (2018–2030)
Figure 48: Market Size of Diabetic Retinopathy in Japan by therapies, USD Millions (2018–2030)
Figure 49: Market Drivers
Figure 50: Market Barriers
Genentech
Regeneron Pharmaceuticals
Kodiak Sciences
Novartis Pharmaceuticals
Adverum Biotechnologies
Graybug Vision
Kubota Vision Inc.
KalVista Pharmaceuticals Ltd.
Novartis Pharmaceuticals
Allegro Ophthalmics
Roche
Boehringer Ingelheim
